Turning TypeOne to The Plan for a World without T1D JDRF Translational Development: Partnering for Success.

Slides:



Advertisements
Similar presentations
Update on Artificial Pancreas Project
Advertisements

West Midlands Academic Health Science Network
West Midlands Academic Health Science Network Mental Health Clinical Priority Event October 10 th, 2013 Peter Lewis Medical Director, Birmingham and Solihull.
West Midlands Academic Health Science Network
Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.
 Objectives ◦ Show video explaining fixed carb ratio insulin therapy. ◦ Show video explaining intensive insulin therapy. ◦ Show video explaining pump.
Past, Present and the Future Rabin Mohanty Consultant Paediatrician Blackpool.
NCI Designation: Expanding Science and Promoting Health in the Region Name Title, Company Date.
CUHP Cambridge University Health Partners (CUHP) unites a world-leading University and three high- performing NHS Foundation Trusts centred on the Cambridge.
JDRF Advocacy: Advancing Life- Changing Therapies
Continuous Glucose Monitoring
The Value of Networking in Allergy & Asthma Research Judah A. Denburg, MD, FRCP(C) Scientific Director and CEO The Allergy Genes and Environment Network.
The Accelerated Cure Project for MS 1 Suffolk University November 7 th, 2011 Robert N. McBurney, Chief Executive Officer A New Model to Speed the Pace.
Irish Health Research: Collaboration and Partnership HSE Regional Library & Information Health Research Seminar Dr. Steevens’ Hospital 11th February 2011.
ICT for Health. Kieran Drain CEO, Tyndall National Institute.
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE
ICARE Member Reports ETP seeks to improve incentives and encourage commercial investment in new therapies. (Treatments reach patients only by commercial.
Global Health Program Guiding Principles April 2002.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
1 Progress Towards an Artificial Pancreas for T1D WILLIAM TAMBORLANE, MD Chief of Pediatric Endocrinology, Yale University, Deputy Director, Yale Center.
An example of a critical system
CURING T1D IS A GLOBAL, COORDINATED EFFORT 555 ACTIVE RESEARCH PROJECTS Note: JDRF research portfolio review September 2014.
Turning TypeOne to The Plan for a World without T1D.
1 Presentation to NIH Scientific Management Review Board October 24, 2013 Concepcion R. Nierras, Ph.D. Assistant Vice President, International Partnerships,
DELAWARE HEALTH AND SOCIAL SERVICES Division of Public Health Public Health and PCMH Karyl Rattay, MD, MS Director Delaware Division of Public Health.
Improving Animal and Human Health by Accelerating Veterinary Centered Entrepreneurship.
Working across sectors Building collaborative eco-systems Lars Sundstrom SARTRE.
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Oracle Health Sciences Global Business Unit Strategy Steve Rosenberg Senior Vice.
2014 “Towards an HIV Cure” symposium Melbourne The Role of a Public-Private Partnership in HIV Cure Mike McCune, MD, PhD University of California, San.
Entrepreneurship in Missouri  Business Recruitment  Business Expansion  Entrepreneurism/New Business Formation Strategies for Economic Development.
GENE THERAPY FOR DIABETES Lindsey Rowbotham Period 7.
Building a Roadmap for Research IT John Brussolo Research IT Program Director September 6, 2012 © 2012 The Regents of the University of Michigan.
BIOMARKERS/BIOSIGNATURES Standards needed for Translational Research 1.Standardized QUESTIONS in Clinical Trials 2.Standardized PRACTICES in advancing.
County Durham Planning Unit – Strategic Plan on a page
Future Pharmaceutical Sciences and Recent Advancement of Medical Sciences Kunio KAWAMURA, Ph.D. Otsuka Pharmaceutical Co. Ltd.
Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.
Diabetes Technology Update
Welcome to TypeOneNation The Plan for a World without T1D Presented by: Carol Oxenreiter Saturday, May 31, 2014.
1 Transforming JDRF Research. Impacting Lives. Julia L. Greenstein, PhD AVP Cure Therapies April 10, 2012.
2 Title Your Name Here Health Technology Center affiliate of The Institute for the Future.
Presentation to the Virtual Ward June 7 th, 2011 Physician eHealth Program David Banh eHealth Ontario.
Instrumenting the Healthcare Enterprise for Discovery Opening Remarks James Mongan, MD President and CEO Partners HealthCare April 11, 2008.
Continuous Glucose Monitors
PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.
The Importance of a Strategic Plan to Eliminate Health Disparities 2008 eHealth Conference June 9, 2008 Yvonne T. Maddox, PhD Deputy Director Eunice Kennedy.
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
Northern Health Strategic Plan – 2009 to Slogan “The Northern way of caring”
Less Until None: A Plan for a World without T1D. 2 LESSUNTILNONE 2 JDRF’s Vision for the Future.
University of Kentucky Center for Clinical and Translational Science (CCTS) November 2015 Stephen W. Wyatt, DMD, MPH Senior Associate Director Center for.
NIH and the Clinical Research Enterprise Third Annual Medical Research Summit March 6, 2003 Mary S. McCabe National Institute of Health.
Pharmacists’ Patient Care Process
IT’S COMPLICATED: T1D Complications BIONIC MAN: My experience in the Artificial Pancreas Clinical Trials Tom Brobson JDRF.
0 International Medical Cluster (IMC), to be established in Moscow, creates a unique framework for developing healthcare business: –IMC activities are.
Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations.
Patient Engagement throughout the Biopharmaceutical Lifecycle: Tips for Effective Patient Advocate/Industry Collaboration to Improve Patient Access and.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
Progress Toward Artificial Pancreas (AP) Systems – A Timeline s 1980s : JDRF.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
Six Sensor CGM Array- Which do you trust?
Translational Research: Case of Istanbul University
NOT A NEW CONCEPT: Really ‘Back to the Future’
Finland, a Global Testbed for Personalized Cancer Research?
Type 1 diabetes and stem cells
A review of the new Eversense CGM System
ACTSI Presentation to MSCR Coloquium
Update on AAMI Foundation Activities
Clinical and Translational Science Awards Program
Jennifer McVean, MD September 23, 2010
Presentation transcript:

Turning TypeOne to The Plan for a World without T1D JDRF Translational Development: Partnering for Success

 JDRF’s Vision for the Future  JDRF’s strategic areas of research  JDRF’s translational strategy  JDRF’s efforts in partnering  Q&A What We’ll Cover

LESSUNTILNONE JDRF’s Vision for the Future

Burden UNTILNONE Danger LESS Complexity LESS Invasive LESS LESS LESS UNTIL NONE

Delivery of Continuous Therapeutic Improvements Side-Effects Complications Patient Burden Glycemic Control Safety Normal Physiology Restored Easier, Safer, Less Worry, Better Life TherapiesCure

Artificial Pancreas A series of systems that will automate insulin dosing and additional hormone delivery

Treat-to-Target (multi-hormone, automated) Low Glucose Suspend Predictive Low Glucose Suspend Treat-to-Range Treat-to- Target (automated) Treat-to-Target (w/meal bolus) APP Strategy: Iterative Increases in Automation 8

Artificial Pancreas Smart Insulin A series of systems that will automate insulin dosing and additional hormone delivery Single dose of insulin that delivers insulin only where and when needed

Artificial Pancreas Smart Insulin Single dose of insulin that delivers insulin only where and when needed Smart Insulin Encapsulation Implantable, beta cell replacement therapies restoring insulin independence without the need for intensive immune suppression

Artificial Pancreas Smart Insulin Encapsulation Encapsulation Implantable, beta cell replacement therapies restoring insulin independence without the need for intensive immune suppression Prevention Slow or stop the progression of T1D before insulin dependence and ultimately eliminate the possibility of ever developing T1D

Artificial Pancreas Smart Insulin Encapsulation Prevention Prevention Slow or stop the progression of T1D before insulin dependence and ultimately eliminate the possibility of ever developing T1D Restoration Beta cell growth protected from immune attack restoring insulin independence without immune suppression

Continuous Therapeutic Improvements Near TermMid Term Long Term Complications Diabetic Eye Disease Predictive Diagnostics Artificial Pancreas Low Glucose Suspend Treat-to-Range Artificial Pancreas Treat-to-Target Multihormone Encapsulation Implantable Islets Smart Insulin Control Prevention Secondary Prevention Prevention Primary: Vaccine Complications Comprehensive Prevention Therapy Restoration New Beta Cell Growth Protected from Immune Attack

Partnering for Success

Question #1 What is translational research? a.Research that catalyzes innovative discoveries to move from bench to the clinic b.Research which enables scientific discoveries to mature into potential products c.Research that progresses through the developmental pipeline d.All of the above

Question #2 What is the “Valley of Death”? a.It’s the location of a JDRF fundraising bike rides b.It’s the home of a leading T1D research institution c.It’s a TV series from which JDRF receives royalties d.Slows development of potential cures for T1D

Question #3 What is one reason partnering is essential to JDRF’s strategy? a.Partnering is more fun b.Partnering get you more friends c.Companies will eventually deliver products to patients d.None of the above

The Plan: Work the Pipeline – Translational Strategy and Partnering for Success

The “Valley of Death” is a Key Part of the Problem “The valley of death has gotten dramatically more fatal over the last few years.” -NewsWeek Basic Research Translational Research Commercialization “Valley of Death” Slows Cures Identifying causes of disease Identifying potential therapeutic targets Understanding disease Human trials Drug launches Post-launch studies Identifying therapies Preclinical research Developing CuresLaunching Products “The valley of death has gotten dramatically more fatal over the last few years.” NewsWeek

JDRF Strategies to Overcome Pipeline Hurdles Enhance Academic and T1D Foundation Collaborations  Eliminate redundancy and improve efficiencies 1 Novel Models for Industry Partnerships  Focused on translational research 2 Engage Strategically Across the Pipeline  Stronger integration of Research and Advocacy efforts and build additional healthcare assessment capacity 3

DELIVERY TO PATIENTS How JDRF collaborates with industry: Project-based Funding

JDRF and The Helmsley Charitable Trust: Sensor Initiative 22 JDRF-HCT Sensor Initiative aims to advance CGM accuracy and reliability towards the next generation artificial pancreas systems. Accurate Reliable Redundant Form factor Safe Enabling artificial pancreas systems Project Goals

Tandem: Novel Dual-Chamber Infusion Pump 23 Create a “dual-chamber” pump device that can simultaneously deliver insulin and other drug therapies. Project Goals Dual Chamber Infusion Pump for insulin and other hormones

Glucagon in a bi-hormonal pump 24 Develop a soluble and stable glucagon drug for use in multi- hormonal artificial pancreas systems Project Goals

How JDRF collaborates with industry: JDRF- Pharma-Academic Partnering 25 Joint-research collaboration programs to fund academic research in partnership with industry. CENTER FOR THERAPEUTIC INNOVATION

How JDRF collaborates with industry: Venture Creation, Seed Funding Advance T1D breakthroughs across the valley of death through a novel, entrepreneurial partnership focused on cures.

Artificial Pancreas Encapsulation Smart InsulinPrevention Restoration Complications

Your Support Capabilities Plan Vision